Recent research has identified the molecular processes of PARP14 as a new prospective therapeutic target for a variety of malignancies, such as prostate cancer, multiple myeloma, ovarian cancer, diffuse large B-cell lymphoma, and breast cancer. This evidence concerns the gene PARP14 and plasma cell myeloma.